Discovery Health, South Africa's largest private health insurance administrator, releases at-scale real-world analysis of Omicron outbreak based on 211 000 COVID-19 test results in South Africa, including collaboration with the SA Medical Research Council (SAMRC) to analyse vaccine effectiveness
Summary of insights:
- Two-dose Pfizer-BioNTech vaccination provides 70% protection against severe complications of COVID-19 requiring hospitalisation, and 33% protection against COVID-19 infection, during the current Omicron wave.
- Reinfection risk: For individuals who have had COVID-19 previously, the risk of reinfection with Omicron is significantly higher, relative to prior variants.
- Severity: Risk of hospital admission among adults diagnosed with COVID-19 is 29% lower for Omicron variant infection compared to D614G infection in South Africa's first wave in mid-2020, after adjusting for vaccination status
- Children: Despite very low absolute incidence, preliminary data suggest children have 20% higher risk of hospital admission in Omicron-led fourth wave in South Africa, relative to D614G first wave
It is important to note that these insights relate to data from the first three weeks of the Omicron-driven wave in South Africa, and consequently should be considered preliminary, and may change with extension of the wave. These data are also confounded by various factors, including high sero-prevalence of COVID-19 antibodies in the South African population as a whole.
Download the presentation linked to this data analysis.
Omicron: A highly transmissible variant causing rapid community spread
The Omicron variant of SARS-CoV-2 was first identified in Southern Africa during November 2021, brought to the attention of the world by scientists in South Africa and Botswana and declared a Variant of Concern by the World Health Organization shortly thereafter. South Africa experienced rapid community spread (concentrated in the Gauteng Province), dominated by the Omicron variant, fuelling South Africa's fourth wave of COVID-19.
"Superb genetic surveillance by the Network for Genomic Surveillance in South Africa identified that Omicron infection accounts for over 90% of new infections in South Africa, and has displaced the formerly dominant Delta variant," says Dr Ryan Noach, CEO of Discovery Health, South Africa's largest private health insurer. "The Omicron-driven fourth wave has a significantly steeper trajectory of new infections relative to prior waves. National data show an exponential increase in both new infections and test positivity rates during the first three weeks of this wave, indicating a highly transmissible variant with rapid community spread of infection."
Real-world data relating to Omicron experience critical to guiding global response
With more than 3,7 million clients, Discovery Health has extensive claims data and private health system utilisation data and is uniquely positioned to generate at scale real-world insights into the impact of COVID-19.
Ryan Noach explains: "There is a social responsibility to update and inform on Omicron given the urgency nationally and globally; and we are in a unique position to do so, given the dominance of the Omicron variant in SA and across Discovery Health's administered medical scheme member base, and the richness and significance of our data, spanning clinical records, vaccination records and pathology test results drawn from our substantial database."
Over the past month, Discovery Health's clinical research and actuarial team have carried out the first at-scale analysis of Omicron's real-world impact.
- Discovery Health partnered with world-leading researchers from the South African Medical Research Council (SAMRC) to provide insights into the vaccine effectiveness of the Pfizer-BioNTech vaccine against infections and severe disease linked to Omicron infection
- Discovery Health further explored various other components of Omicron infection including the rate of spread; severity of illness relative to prior waves; clinical manifestations; and the relative reduction of risk conferred by prior proven COVID-19 infection.
The detailed vaccine effectiveness analysis in collaboration with the SAMRC includes more than 211,000 COVID-19 test results, 41% from adult members who had received two-doses of the Pfizer-BioNTech vaccine. Approximately 78,000 of these COVID-19 test results were attributed to Omicron infections, over the period 15 November to 7 December 2021.
"To-date laboratory analysis has provided early insights into potential reduction in the effect of neutralising antibodies against the Omicron variant," says Dr Noach. "However there remains urgency around establishing real-world data on Omicron across all areas of impact. Our research into Omicron is based on a rich and significant sample, and also relates directly to the experience of the first country in the world to face a COVID-19 wave driven by Omicron," says Dr Noach.
(1) Two-dose Pfizer-BioNTech vaccination provides significant protection against hospitalisation in individuals with Omicron variant infection
Discovery Health's research on the effectiveness of two-dose Pfizer-BioNTech vaccination in preventing severe disease and hospitalisation as a result of Omicron variant infection has been carried out by Discovery Health's actuarial team in collaboration with leading scientists at the South African Medical Research Council.
"We used a test-negative design methodology to establish the Pfizer-BioNTech COVID-19 vaccine's real-world effectiveness against hospital admission from Omicron infection," said Shirley Collie, Chief Health Analytics Actuary at Discovery Health. "We carried out three carefully constructed sensitivity analyses with consistent results across each analysis supporting the veracity of our findings. These findings were reviewed by scientists at the SAMRC with whom we have collaborated on multiple areas of our pandemic-related research to date."
The result shows that vaccinated individuals who received two-doses of the Pfizer-BioNTech vaccine have 33% protection against infection, relative to the unvaccinated, in the first weeks of South Africa's Omicron-driven fourth wave. This represents a significant drop from the 80% protection against infection afforded during the earlier period, probably on the basis of lower antibody susceptibility, following the extensive Spike Protein mutations in the Omicron variant.
Encouragingly though, the result shows that these same vaccinated individuals who received two-doses of the Pfizer-BioNTech vaccine have 70% protection against hospital admission in this same time period. Whilst protection against hospital admission reduced from the highs of 93% in South Africa's Delta-driven variant, 70% is still regarded as very good protection.
President of the SAMRC, Professor Glenda Gray said, "We are extremely encouraged by the results of Discovery Health's analysis. It is extremely important to be able to demonstrate to the public that in a real-world setting - in the presence of a highly transmissible new COVID-19 variant - the Pfizer-BioNTech vaccine provides good protection against severe disease and hospitalisation."
Furthermore, the analysis demonstrates that protection against hospital admission is maintained across all ages, in people from 18 to 79 years, with slightly lower levels of protection for the elderly (67% in people aged 60 to 69 and 60% for people aged 70 to 79). Protection against admission is also consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia, and other cardiovascular diseases.
(2) Omicron reinfection risk significantly higher compared to prior variants
"With each successive wave of COVID-19 infection in South Africa, we have investigated the durability of immunity following previous infection with COVID-19 - i.e., the risk of reinfection," explains Shirley Collie, Chief Health Analytics Actuary at Discovery Health.
"Overall, the risk of re-infection following prior infection has increased over time, with Omicron resulting in significantly higher rates of reinfection compared to prior variants."
- People who were infected with COVID-19 in South Africa's third (Delta) wave face a 40% relative risk of (re)infection with Omicron.
- People who were infected with COVID-19 in South Africa's second (Beta) wave face a 60% relative risk of (re)infection with Omicron.
"While individuals who had a documented infection in South Africa's first wave, and therefore were likely to have been infected with the D614G SARS CoV-2 virus, face a 73% risk of reinfection relative to those without prior documented infection." adds Collie.
(3) Risk of severe disease and hospitalisation significantly lower in Omicron infection compared to prior variants
Discovery Health has investigated the Omicron variant's clinical impact relative to other SARS-CoV-2 variants.
"Epidemiological tracking shows a steep trajectory of new infections, indicating Omicron's rapid spread, but so far with a flatter trajectory of hospital admissions, possibly indicating lower severity," explains Dr Noach. "This lesser severity could however be confounded by the high seroprevalence levels of SARS CoV-2 antibodies in the general South African population, especially following an extensive Delta wave of infections."
Collie adds, "Adults are experiencing a 29% lower admission risk relative to South Africa's first wave of infection, dominated by D614G, in early 2020. Furthermore, hospitalised adults currently have a lower propensity to be admitted to High care and Intensive Care Units, relative to prior waves"
(4) Preliminary observations on Omicron experience in children
"Notwithstanding the fact that children continue to show a very low incidence of severe complications following COVID-19, Discovery Health's data indicate that children under age 18 have 20% higher risk of admission for complications of COVID-19, when infected with Omicron," says Collie. "This is early data and requires careful follow up. However, this trend aligns with the South Africa's National Institute for Communicable Diseases (NICD) warning in recent days that during South Africa's third wave of infection (June to September 2021) they had seen an increase in paediatric admissions and now, in the fourth wave, they are seeing a similar increase in admissions for children under five. Anecdotal reports from hospitals in South Africa indicate that most COVID-19 diagnoses in children admitted to hospital are co-incidental - many children that are admitted for non-COVID related conditions, and are not experiencing COVID-19 complications, test positive for COVID-19 on routine screening tests."
It is also important to note that Discovery Health's analysis shows that the risk of children testing positive for COVID-19 infections was significantly lower than in adults. "Children were 51% less likely to test positive for COVID-19 relative to adults in the Omicron period, and overall, the risk of children being admitted to hospital for COVID-19 complications remains low," Collie adds.
Where children require admission for complications of COVID-19, the primary diagnoses are bronchiolitis and pneumonia, often with severe gastrointestinal symptoms and dehydration.
"The majority of children present with mild disease with symptoms such as a sore throat, nasal congestion, headache and fever which resolves within three days," adds Dr Noach, based on anecdotal consensus sourced from the treating healthcare professionals.
Vigilance and vaccination remain our primary means of overcoming the pandemic
"We are encouraged that the Pfizer-BioNTech vaccine continues to offer high levels of protection from severe COVID-19 illness," said Dr Noach.
"We are hopeful that the current experience of COVID-19 caused by the Omicron variant - mild disease for the most part - will remain unchanged. Notwithstanding this, we remain concerned that health systems could still come under pressure considering the high rate of spread of Omicron, and consequent high sudden infection burden. Our research teams will continue to monitor the progression of the fourth wave in this regard, and we will depend on the continued stewardship of the National Department of Health to ensure health systems can cope with the disease burden."
"The importance of COVID-19 vaccination in the current context is unquestionable, as conclusively demonstrated in the research. At the same time, we urge adherence to the important non-pharmaceutical measures of distancing, avoiding public gatherings, mask wearing and hygiene precautions."
"We extend our sincere thanks to all the healthcare professionals, scientists and support staff working on the pandemic's frontlines, delivering outstanding care and giving their all to bring our country and the world closer to overcoming the COVID-19 pandemic."
About Discovery Ltd
Discovery Limited is a South African-founded financial services organisation that operates in the healthcare, life assurance, short-term insurance, savings and investment and wellness markets. Since inception in 1992, Discovery has been guided by a clear core purpose - to make people healthier and to enhance and protect their lives. This has manifested in its globally recognised Vitality Shared-Value insurance model, active in 31 markets with over 20 million members. The model is exported and scaled through the Global Vitality Network, an alliance of some of the largest insurers across key markets, including Asia-Pacific, Europe, North America and South America.
In 2021 Vitality Health International (VHI) introduced shared value health insurance to employer groups operating in Ghana, Kenya, Nigeria and Zambia, as well as Travel for Treatment service to the rest of Africa.
Discovery trades on the Johannesburg Securities Exchange as DSY. Discovery Group is the holding company of Vitality Group in the USA and of Vitality UK.
About Discovery Health
Discovery Health (DH) is South Africa's largest private health insurance administrator, providing comprehensive healthcare insurance to more than 3.7 million people in South Africa. Discovery, through its proprietary wellness programme, Vitality, partners with leading global insurers in Asia-Pacific, Europe, North America and South America servicing more than 20 million clients globally, enabling them to live healthier, longer lives. Due to its scale and prominence in the private healthcare environment Discovery Health has unparalleled access to a unique data set in South Africa encompassing full electronic health records, wellness data, and vaccination data for these insured lives. Discovery Group is the holding company of Vitality Group in the USA and of Vitality UK.
About the SAMRC
The South African Medical Research Council (SAMRC) is dedicated to improving the health of people in South Africa, through research, innovation, and transformation. The scope of research includes laboratory investigations, clinical research, and public health studies. Established in 1969, the SAMRC provides evidence-based information to inform health policy, practice, and research translation. Their research funding programs provide research grants and scholarships to build health research capacity, while through health innovation programs, they develop pioneers in cutting edge genomic research, the development of treatment regimens, vaccines, diagnostic tools, and new drugs and devices. Aligned with national health priorities, the SAMRC COVID-19 response includes a broad spectrum of public health studies, surveillance and epidemiology studies.
Interested in knowing more or reporting on these findings?
Please contact us on MEDIA_RELATIONS_TEAM@discovery.co.za to request any updated data available since publication and any further context required.
Did you find this post useful?
You may also be interested in reading our recent post on the Pfizer-BioNtech COVID-19 vaccine's real-world effectiveness in protecting against COVID-19 admission and mortality in the Discovery Health client population. This report on the protective effects of COVID 19 vaccination follows a massive analysis of millions of data points across the comprehensive wellness, healthcare and vaccine data encompassing 2,1 million adult scheme members, administered by Discovery Health.
All information shared on this page is based on perspectives gained from analysis of figures and trends emanating from discovery health's data pool. The analysis, which is conducted by discovery health's actuarial and data scientist team, aims to encourage industry dialogue. This content is shared for educational and informational purposes only. It does not constitute peer-reviewed, published scientific research, and hence should not be interpreted as such or used as a basis for altering treatment decisions.
Super immunity? Discovery Health data analysis shows 98% drop in risk of COVID admission for people who have both recovered from COVID-19 and who are fully vaccinated (Pfizer two-dose vaccine)
03 November 2021
Authors: Shirley Collie (Chief Healthcare Analytics Actuary, Discovery Health) and Jared Champion (Senior Actuary, Discovery Health)
Discovery Health's investigation into the Pfizer COVID-19 vaccine's real-world effectiveness takes a closer look at the impact of full vaccination on those who have recovered from COVID-19. Our investigation shows that for people in this group, the absolute risk of COVID-19 admission is reduced by 98%.
Getting COVID-19 puts a person at equal or much higher risk of adverse events than COVID-19 vaccination
03 November 2021
Authors: Shirley Collie (Chief Healthcare Analytics Actuary, Discovery Health), Lizelle Steenkamp (Head of Risk Intelligence, Discovery Health) and Jared Champion (Senior Actuary, Discovery Health), Tommy Chen (Actuary, Discovery Health)
Discovery Health's investigation into the risk of adverse events, either following COVID-19 vaccination or when infected with COVID-19 disease. We show that contracting COVID-19 carries the highest risk by far, of experiencing adverse conditions.
Pfizer vaccine's real-world effectiveness in protecting against COVID-19 admission and death in the Discovery Health client population
03 November 2021
Authors: Shirley Collie (Chief Healthcare Analytics Actuary, Discovery Health) and Jared Champion (Senior Actuary, Discovery Health)
Discovery Health's investigation into the Pfizer COVID-19 vaccine's real-world vaccine effectiveness shows a 92% effectiveness in reducing COVID-19 hospital admission risk and 94% effectiveness in preventing the risk of COVID-19 death, between 14 days and 3 months after receiving the second dose.